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Abstract. Constitutive activation of PI3K/AKT signaling pathway has been observed in Acute Myeloid Leukemia 
(AML) that caused by the mutation of Fms-like Tyrosine Kinase 3 in internal tandem duplication (FLT3-ITD). 
Constitutive activation of AKT resulted in the regulation of apoptosis by the growth of abnormal cells that 
uncontrollably (AML blast). In our previous work we had consider a mathematical model of  PI3K/AKT signaling 
pathways in phosphorylation AKT. In this paper we carry out a modification of the model by including synthesis and 
degradation of proteins as well as the effect of small molecule inhibitor of PI3K/AKT pathways. Perifosine is one of 
a small molecule inhibitor which has been widely known in the treatment of AML as AKT inhibitor.  Our simulation 
result suggested that the administration of Perifosine may reduce the activity of AKT Phosphorylation. This result 
also support of the hypothesis that PI3K/AKT pathways is a potential target theraphy in AML.  
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INTRODUCTION 
      Acute Myeloid Leukemia (AML) is characterized by clonal expansion of early myeloid progenitor cell 
which some subtypes can be classified by distinct molecular and cytogenietic abnormalities [1]. Most cases of 
AML showed deregulated activity of the Phospoinositol-3-kinase (PI3K)/ protein kinase B (AKT)/mammalian 
target of rapamycin (mTOR) signal transduction. In the process of hematopoiesis regulation, PI3K, AKT, and 
mTOR are key component in a complex network of signaling proteins that promotes cell growth, proliferation, 
and survival. Overactivation of the PI3K/AKT/mTOR pathway has consistently been identified in AML which 
the most frequently identified transforming event are activating mutation in the receptor tyrosine kinase, Fms 
like tyrosine kinase 3 (FLT3) on the domain juxtamembrane internal tandem duplication (ITD) [2 – 5]. FLT3 
activation promotes several downstream signaling pathways including PI3K/AKT/mTOR.  In normal 
conditions, low level activation of PI3K/AKT/mTOR pathways maintains cell survival but does not drive 
growth of cell division. PI3K activation is initiated through extracellular binding of ligands, which in turn 
triggers the activation of corresponding receptor tyrodine kinases (RTK) [4].  
PI3K is a family of enzyme  that have crucial rule in mechanism of cell regulation. The family of PI3K has 
been categorized into three classes, which class I PI3K is the best understood and are key players of multiple 
intracellular signaling networks that integrate a wide variety of signals and corelated with hematology 
malignancy. The most important PI3K substrate is phosphatidynositol 4,5 biphosphate (PtdIns(4,5)P2) (PIP2), 
which is phophorylated to yield phosphatidylinositol 3,4,5 triphosphate (PtdIns3,4,5P3) (PIP3).The most 
dominant downstreams effectors of PI3K are AKT, a sherine/threonine protein kinase contains an NH2 terminal 
pleckstrin homology (PH) domain, which interacts with PIP3 and phospoinositide dependent kinase-1 (PDK1) 
at the plasma membrane resulting in AKT phosphorylation at threonine 308. For full activation, AKT also 
phosphorylation by mechanistic target of rapamycin complex 2 (mTORC2) at serine 473. In AML constitutive 
activation PI3K/AKT is a common feature, that is about 50 to 70 % of patien with AML display phosphorilation 
of both Thr 308 and Ser 473 AKT.  
Negative regulator of PI3K/AKT signal is a phosphatase and tensin homologue deleted on chromosome ten 
(PTEN). PTEN is a protein phosphatase that dephosphorylation the PIP3 back into PIP2. Dephosphorylation is 
essential to inhibit the signaling pathways of AKT. Loss of PTEN function results in the accumulation of PIP3 
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and its downstream pathways. Another negative regulator is protein phosphatase 2A (PP2A) that can directly 
cause dephosphorylation at AKT. Dephosphorylation of AKT can also caused by PH domain leucine-rich repeat 
protein phosphatase (PHLPP) [6]. PHLPP can cause dephosphorylation of AKT phosphorylation on one site, 
which is Ser 473 or  in both site site Thr 308 and Ser 473. In AML, the deregulation of the PI3K/AKT pathway 
is caused due to excessive activation of PI3K, PTEN deletion/ inactive, PP2A deletion/loss. These deregulation 
caused overactivation of AKT phophorylation that necessary for increased cell survival, proliferation, and 
leukemic transformation. Constitutive activation of AKT also phosphorylated and inhibit the transcription factor 
FOXO3a that caused its inactive [7]. FOXO3a is a transcription factor that plays an important role in the process 
of apoptosis and cell cycle regulation. Because  of dysregulation of the PI3K/AKT signaling pathways has been 
observed in AML, this pathways and its downstreams effectors are considered to be promising targets for 
therapy.  
 Referring to our previous work [8], in this paper we modeled and simulated the AKT phosphorylation as a 
result of FLT3-ITD mutations that activate PI3K/AKT signaling pathways in cases of AML that carry out a 
modification of the previous model by including synthesis and degradation of proteins as well as the effect of 
small molecule inhibitor of PI3K/AKT pathways.  
 
 
TARGETING PI3K/AKT IN AML THERAPY 
 
Dysregulation of PI3K/AKT/mTOR pathway resulting from oncogenes amplification, oncogene activating 
mutations, inactivation of tumar suppresor genes, or upstream activation of RTK, has been demonstrated in a 
range of human malignamcies. In AML, this dysregulation commonly caused by the activating mutation of 
FLT3-ITD. There are a number of small molecule inhibitor of elements of this pathway in development, 
including PI3K inhibitor, AKT inhibitor, mTOR inhibitor, and dual mPI3K/mTOR inhibitor [1,3-5,7]. AKT is a 
key effector of PI3K/AKT pathways, but until now AKT inhibitor have been rarely tested in either preclinical 
nor clinical settings [5]. PI3K phosphorylates PIP2 generating PIP3 that in turn recruits proteins containing PH 
domains, such as AKT to the cell membrane. While in the cell membrane, AKT phosporylates at Thr308 and 
Ser473 for its full activation and generation of downstream pathways that promotes of cell prliferation and 
antiapoptotic signaling via several effectors. Downstream effects of this signal included inactivation of 
transcription factor GSK3 and FOXO3a through phosporylation that caused its retained in the cytoplasma and 
its transcriptional activity is prevented. AKT also contributes to chemotherapy resistance of AML blast [1]. 
Taken together, these fact provide a firm rationale for the development of PI3K/AKT inhibitor as therapies of 
AML. 
To date, several small molecule inhibitors of PI3K/AKT pathway in AML have been developed, which 
demonstrated significant efficacy for reducing cell proliferation, inducing apoptosis and/or enhancing the 
efficacy of other therapies in various preclinical models of AML. The list of such inhibitors can be found at [1, 
4,5,7]. Some AKT inhibitors obtained from that list are Perifosine, degeulin, triciribine, MK2206, GSK690693, 
and GSK2141795. Perifosine, the phospholipid analog, inhibits AKT by altering lipid rafts and preventing the 
membrane localization of AKT, resulting in apoptosis of AML cell lines and enhancement of etoposide 
cytotoxicity.  Perifosine  interact with AKT PH domain, preventing the membran recruitment and activation of 
AKT. The purine nucleoside analog, triciribin (TCN-PM) inhibits AKT phosporylation by interfering AKT PH 
domain and preventing its membrane localization. Degeulin is a nonspesific AKT inhibitor induced cell cycle 
arrest or apoptosis, and enhanced the sensitivity of AML cell lines or blast to etoposide or cytarabine while 
having relatively minimal efffects on normal CD34+ cells. Another strategy utilized to block AKT activation has 
been the development of small molecule inhibitors such as MK2206, GSK690693, and GSK2141795. 
 
MATHEMATICAL MODEL 
This mathematical model is a modification of the previous model with the additional presence of synthesis 
and degradation of proteins in the reaction.  The representation of the biochemical reaction shown in Figure 1 
below: 
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FIGURE 1.  Schematic representation of the PI3K/AKT signaling module that  
drive oncogenesis in AML cells [5]. 
 
As shown in figure 1, activation of PI3K by receptor stimulation  results in the production of PtdIns(3,4,5)P3 
at the plasma membrane. AKT subsequently translocates to the plasma membrane where it is phosphorylated by 
PDK1 and the mTORC2 complex at Thr308 and Ser473. On phosphorylation, AKT is released into the 
cytoplasm where it can both inhibitory phosphorylate multiple substrates, including TSC1/2 and/or PRAS40, 
FoxO transcription factors and GSK-3, and induce the activity of other substrates, such as mTOR as part of the 
mTORC1 complex. Negative regulators of the PI3K/AKT signaling module include PTEN, SHIP1, 
Ins(1,3,4,5)P4, PP2A, and PHLPP1/2. Here, we will  modified our previous model of AKT phosphorylation that 
observed protein synthesis and degradation in the reactions and  not observe a downsream pathways of AKT. A 
simplify schematic diagram of  the PI3K/AKT signaling pathways to decsribed our mathematical model is 
shown in Figure 2. 
     
FIGURE 2. Schematic diagram of the biochemical reaction in PI3K/AKT signaling Pathway 
 
From the schematic diagram in Figure 2, the chemical reaction  can be  divided in two levels of 
phosphorylation – dephosphorylation.The first level biochemical reactions is phosphorylation of PIP2 by PI3K 
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phosphorylation AKT by PIP3 as enzyme to form AKTp and dephosphorylation of AKTpp by phospatase PP2A 
back to AKT (see [8] for detail derivation). 
 We denote the concentration of reactans :  = [PIP2] = Concentration of PIP2,  = Concentration of PIP3, 
 = Concentration of AKT,  = Concentration of AKTp. Then,  modified the previous model of irreversible 
Michaelis Menten equation in [8], we have a mathematical model of PI3K/AKT signaling pathway is given by 











where ,     are known as  Michaelis-Menten constant. 
The set of kinetic rates  and their kinetic rate constant are given in Table 1.  
 
 
TABLE 1. Kinetic rate constant 
Parameter Description Unit Range Value used References 
 Synthesa/production of 
PIP2 
Cell mol-1s-1  0.008 10 
 Degradation of PIP2    0.0013 9 
 Activation/phosphorylation 
of AKT  
  0.2 8 
 Association of complex 
PIP2:PI3K 
Cell mol-1s-1   8 
 Dissociation of complex 
PIP2:PI3K 
   0.1 8 
 Association of complex 
PIP3:PTEN 
Cell mol-1s-1    8 
 Dissociation of complex 
PIP3:PTEN 
   0.1 8 
 Deposphorylation of PIP3    0.1 8 
 Phosphorylation of AKTp    1 8 
 Association of complex 
PIP3:PAKT 
Cell mol-1s-1  2.6  8 
 Dissociation of complex 
PIP3:AKT 
  0.1 8 
 Association of complex 
AKTp:PP2A 
Cell mol-1s-1   8 
 
 Dissociation of complex 
AKTp:PP2A 
  0.1 8 
 Dephosphorylation of 
AKTp 
  1.5 8 
 Production/synthesa of 
AKT 
Cell mol-1s-1  0.0015 9 
 Degradation of PIP3   0.02 9 
 Degradation of AKT   0.0013 9 
 Degradation of AKTp   0.00167 9 
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We now simulate our mathematical model using the ode45 routine generating using Matlab. Parameters used 
on this simulation are depicted in Table 1 and the initial concentration of reactan we also refer to[8] given in 
Table 2.  
 
TABLE 2. Initial Concentration of the protein  
Protein Concentration (nM)  
Range (nM) 
PI3K 10 10 – 100 
PTEN 270 0.1 – 350  
PP2A 150 4 – 150 
PIP2 700 700 – 800 
AKT 700 10 – 900 
 
Figure 3 shows the simulated protein activities used parameters on Table 1 and Table 2.  
 
  
(a)                                                                         (b) 
 
(c)                                                                         (d) 
 
 
FIGURE 3. Simulated system dynamics of the protein activity.(a) Concentration of PIP2,  
(b). Concentration of PIP3, (c). Concentration of AKT, (d) Concentration of AKTp. 
 
The initial condition is [PIP2] = 700 nM, [PI3K] = 100 nM, [PTEN] = 300 nM, [ AKT] = 100 nM, [PP2A] = 
30 nM, [PIP3] = 0, [AKTp] = 0. In the initial conditbion of PI3K, we choose maximal concentration at 100 nM 
due to  increased PI3K activity in AML patiens [4]. The concentration of PIP2 convert to PIP3, so that the 
concentration of PIP3 increase and reach the maximum level within 150 second. After reach thme maximal 
level, PIP3 will decline caused by degradation of PIP3. The level of PIP3 controlled the phosphorylation, 
AKTp, activation of AKT. AKTp  reach its maximal level in about 500 second and will decline after  the 
decrease of PIP3 level. 
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THE EFFECT OF AKT INHIBITOR 
PI3K/AKT pathways  is a potential target for theraphy of AML patients. One of the most common small 
molecule inhibitor that  inhibit AKT is Perifosine. Furthermore, we assume that Perifosine act as pure 
competitive inhibitor in the reaction of enzyme-inhibitor-substrate complex. With these assumption, as describes 
by Sauro in [11], if AKT concentration is increased, it posible for AKT to eventually out compete Perifosine, so 
that Perifosine alters the Michaelis constant  but not the . Therefore the equation for Perifosine inhibitor is 
shown in equation (2). 




with  is the Perifosine and   is the Perifosine binding dissociation constant.  So if , the equation reduces 
to   as in equation (1). Now, use the equation (2) to equation (1), we have the simulation result of AKTp 




FIGURE 4. Concentration of AKTp with different concentration of Perifosine, 
I = 0 nm (blue), I = 1 nM (Black), and I = 5 nM  (green) with   
 
Figure 4 gives simulated dynamcs of AKTp when different concentration of Perifosine is added into the system. 
The AKTp concentration is reduced proportionally when more concentration of Perifosine was added into the 
system.  
CONCLUSIONS AND FUTURE WORK 
In this work we carry out a modification of our previous model by including synthesis and degradation of 
proteins as well as the effect of small molecule inhibitor of PI3K/AKT pathways. We than consider Perifosine 
as AKT inhibitor that interact with AKT PH domain, preventing the membrane recruitment and activation of 
AKT. This model not consider protein substract in the downstream pathways of AKTp and crosstalk with 
another pathways. The administration of Perifosine as inhibitor of AKT in AML perhaps is an effective therapy 
such as simulation result in Figure 4. Mathematical analysis of this model is under preparation. Further studies 
required to determine the other target of small molecule inhibitor or multi targeted inhibitors so that the most 
effective combination to eradicate AML can be developed. In the future work we will also observe the other 
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